Turn Therapeutics (TTRX) Assets Average (2025 - 2026)
Turn Therapeutics' quarterly Assets Average came in at $15.4 million in Q1 2026, up 87.16% quarter-over-quarter from $8.2 million in Q4 2025.
Turn Therapeutics has reported Assets Average for 2 years, with the latest figure at $15.4 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average changed N/A year-over-year to $15.4 million; the trailing twelve-month figure through Mar 2026 stood at $15.4 million (changed N/A YoY), and the FY2025 full-year result was $7.1 million, changed N/A from the prior year.
- Assets Average for Q1 2026 stood at $15.4 million, up from $8.2 million in the prior quarter.
- The five-year high for Assets Average was $15.4 million in Q1 2026, with the low at $8.2 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Turn Therapeutics | 188.06 Mn | 188.06 Mn | - | 15.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.40 Mn |
| Dec 31, 2025 | 8.23 Mn |